C4 Therapeutics(CCCC) - 2023 Q4 - Annual Report

Multiple Myeloma Peripheral T-cell Lymphomas Mantle Cell Lymphoma CFT1946: Degrading BRAF V600X to Treat Melanoma, Colorectal, and Non-small Cell Lung Cancers 8 remains a high unmet need for those who relapse after, or do not respond to, approved BRAF inhibitors. We are evaluating CFT1946 in a variety of BRAF V600X solid tumors, including melanoma, CRC, and NSCLC, where current standard of care BRAF inhibitor for these specific indications are dabrafenib with trametinib for melanoma in the first-line settin ...